Glenmark Pharmaceuticals share price is in demand on Thursday after the company received a positive inspection report from the US FDA. The stock climbed 2% to ₹1,958 during intraday trade and continued its upward trend throughout the day.

At around 10:49 AM, the stock was trading at ₹1,950, up 1.5% from the previous close. Meanwhile, the Nifty50 was also trading near record highs.

US FDA Gives VAI Status to Glenmark’s Monroe Facility

Glenmark informed exchanges that it has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status for its formulations manufacturing facility in Monroe, North Carolina.

The inspection was carried out between June 9 and June 17, 2025. With this clearance, the company said it will restart commercial manufacturing at the site.

Glenmark Pharma Q2 FY26 Results Boost Sentiment

Earlier on November 14, Glenmark reported strong financial results for Q2 FY26:

• PAT: ₹610.43 crore, up 72.2% YoY (helped by a licensing deal with AbbVie for ISB 2001)
• Revenue: ₹6,046.87 crore, up from ₹3,433.8 crore in Q2 FY25
• Total expenses: ₹3,894.98 crore, compared to ₹3,000.64 crore last year

The sharp jump in profit and revenue has strengthened investor confidence in the company’s growth prospects.

Also Read: Info Edge to Invest ₹100 Crore in Redstart Labs!

Glenmark Pharma Share Price Movement

Glenmark Pharmaceuticals share price (NSE: GLENMARK) was trading at ₹1,941.30 as of 12:50 PM on November 27, up 1.04% for the day. The stock opened at ₹1,924.70 and moved between a high of ₹1,958.00 and a low of ₹1,922.30 during the session. Glenmark currently has a market capitalisation of ₹53,360 crore, a P/E ratio of 54.26, and offers a dividend yield of 0.19%. The stock has traded within a 52-week range of ₹1,275.50 on the lower end to ₹2,284.80 on the higher end.

Conclusion

Glenmark Pharma’s latest rally is supported by 2 major positives: a clean US FDA inspection that allows its US facility to resume production, and strong Q2 earnings growth. With improving regulatory clarity and solid financial momentum, the stock is likely to remain on investors’ radar.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.